Trial Profile
A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-Line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Jan 2015 Status changed from active, no longer recruiting to completed according to results published in the BMC Cancer.
- 01 Oct 2012 Status changed from recruiting to active, no longer recruiting according to results published in the BMC Cancer.
- 06 Sep 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.